After graduating from Purdue University in 1990, David was commissioned as an intelligence officer in the United States Navy. He served on active duty for eight years and as a reservist for twelve, retiring in 2010. Serving in the aviation squadron VS-37 deployed with the USS Kitty Hawk Battlegroup, David supported humanitarian and operational missions during Operation Restore Hope, Somalia and supported strike-planning execution for Joint Coalition airstrikes in Iraq. David’s service in VS-37 enabled him to gain extensive expertise in acoustic systems and technologies used to detect and track threat submarines.

David’s second and third Navy assignments were at the Defense Intelligence Agency/Chairman of the Joints Chief of Staff, Pentagon and The Office of Naval Intelligence, respectively. During these assignments, David managed over 20 intelligence officers and analysts, developing over 100 all-source intelligence assessments for DoD leadership and operational commanders. During his time in the Navy, David received 3 Naval Intelligence subspecialty qualifications, 5 joint awards and 7 personal awards, while completing his Master of Science Degree in 1997.

Upon leaving active duty in 1998, David began working for Science Applications International Corporation (SAIC) where he subsequently managed the Navy’s investment strategy program contract, leading over 100 professional engineers, technical domain experts, scientists and analysts across 11 companies in warfare and intelligence analysis efforts. During this time, David employed incisive and broad-ranging program management and technical skills to support the Chief of Naval Operations (CNO) in areas of operational requirements development, mission needs assessment and analysis of critical areas of U.S. warfighting vulnerabilities.

During his time as a Vice-President at SAIC, David directly managed all CNO support work and grew the program from $4M annually to nearly $20M. David won numerous smaller procurements and two major Navy procurements, totaling $255M and $80M, respectively. During his time at SAIC, David received 9 corporate awards and earned 6 promotions.

Upon leaving SAIC, David began working on the innovative cancer detection concept that subsequently led to the creation of UMM. Upon successful fundraising efforts, Mr. Johnson began serving as the full-time CEO of UMM, where his unique blend of leadership, team-building skills, management and technical acumen in acoustic and targeting technologies have enabled the current success of the company in developing its breakthrough cancer detection technology.

After graduating from Purdue University in 1990, Aaron was commissioned as an officer in the United States Navy where he served with distinction for nine years. Aaron was a Naval Flight Officer and an Electronic Warfare Officer, his experience in the latter directly prepared him for his CTO role in UMM by providing a background in the use of distributed, multi-sensor arrays to identify and locate targets. His Naval service included multiple overseas tours of duty including service in both the Middle East and the Balkans.

After leaving the Navy, Aaron went to Georgetown University where he took an MBA with a concentration in Finance. He then spent several years at Starwood Hotels working his way up through various roles from corporate treasury and finance to underwriting and real estate development. The experience at Starwood led to a role in Private Equity as Portfolio Manager at RLJ Development, LLC (now RLJ Lodging Trust) where he got a broad exposure to all financial aspects of a private equity firm. In 2009 he left RLJ for a new role with GE Capital underwriting and managing a portfolio of loans for the Franchise Finance group. After GE made the decision to shut down the business Aaron decided to go back to the Private Equity industry working for JPMorgan in fund administration.

While at JPMorgan, Aaron was contacted by his old friend Dave Johnson who had just founded a company called Ultrasonic Medical Mapping. Aaron began working part time with the members of UMM on structuring the company to be able to attract investment. After a few false starts, Aaron was able to secure the initial round of funding and transitioned to a full-time role with UMM. Aaron was responsible for directing the technical work on the UMM preclinical prototype, laying the groundwork for the firm’s current efforts.

As UMM’s Scientific Advisor and Chief Science Officer of the Pancreatic Cancer Action Network (PANCAN), Dr. Matrisian brings extensive experience and a passion for cancer research, combined with business training, to lead the organization’s Scientific & Medical Affairs teams as they strive to reach the goal of doubling pancreatic cancer survival by 2020.

Prior to joining the Pancreatic Cancer Action Network, Dr. Matrisian put her scientific training to work for 25 years leading a research laboratory dedicated to understanding cancer metastasis. She has published more than 220 original scientific articles and trained more than 30 young scientists who have gone on to join the fight against cancer in the academic, biotechnology, pharmaceutical, government and nonprofit sectors.

Dr. Matrisian was the founding chair of the department of cancer biology in the School of Medicine at Vanderbilt University, the president of the American Association for Cancer Research (AACR) and a special assistant to the director of the National Cancer Institute at the National Institutes of Health. She was elected to the AACR Academy, which recognizes and honors distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer.

Dr. Matrisian received a PhD in molecular biology from the University of Arizona and an MBA from the Owen Graduate School of Management at Vanderbilt University.

Suresh Chari, M.D. is an UMM Medical Advisor and a Professor of Medicine with the Mayo Clinic College of Medicine. He is also a consultant in the Division of Gastroenterology and Head of the Pancreas Interest Group in the Division of Gastroenterology and Hepatology.

Dr. Chari has a broad interest in diseases of the pancreas and his NIH-funded research focuses on the role of diabetes and hyperglycemia as a marker of undiagnosed pancreatic cancer. Dr. Chari’s additional areas of clinical research involve understanding the clinical spectrum of autoimmune pancreatitis and in in cystic tumors of the pancreas including their classification, prevalence and natural history.

His current project, "Pancreatic Cancer-induced Diabetes: A Clue to its Early Diagnosis" has the long-term programmatic goals to facilitate early detection of pancreatic cancer. Towards this end the research is focused on a) identifying groups of individuals who are at higher than average risk of having asymptomatic sporadic pancreatic cancer and b) developing biomarkers that can identify early pancreatic cancer.

Michael Levy, M.D. is an UMM Medical Advisor and a Professor of Medicine with the Mayo Clinic College of Medicine. He is a gastroenterologist and is also affiliated with Veterans Affairs Black Hills Health Care System - Fort Meade. He received his medical degree from University of South Carolina School of Medicine and has been in practice for more than 20 years.

Working with Dr. Suresh Chari, Dr. Levy has assisted in UMM in broadly outlining a clinical study to be conducted at the Mayo Clinic that will compare UMM’s cancer detection technology with existing systems in use today.